-
Former CEO, consumer products companies; branding/marketing expert; former private equity partner and chair of portfolio companies; director of public, private and non-profit institutions.
President, Barnegat Group LLC; Managing Director and Operating Advisor, North Castle Partners, LLC; Director and Chair, Nominating and Governance Committee, Eli Lilly & Co., Ford Motor Company; Presiding Director, Finance Committee Chair, The New York Times Company.
Former CEO, Tropicana; CEO, Nabisco Biscuit Company.
Wellesley College B.A.; Harvard Business School M.B.A.
Ellen Marram is a member of Brock Capital Group LLC and is the president of the Barnegat Group LLC, her business advisory firm. From 2000-2005, she was a Managing Director of North Castle Partners, a private equity firm focused on investments in healthy living and aging where she served as Chairman of several portfolio companies. She currently serves as an operating advisor to North Castle and to Physic Ventures, a venture capital firm.
Ms. Marram was President and Chief Executive Officer of Tropicana and the Tropicana Beverage Group from 1993-1998. she transformed the business from a Florida juice company to a market driven, health-focused global juice business,number one in worldwide sales and profits. During her tenure, Tropicana nearly tripled its shareholder value and was sold to PepsiCo in 1998 for $3.3 billion. From 1988-1993, Ms. Marram was the President and Chief Executive Officer of the Nabisco Biscuit Company where she consistently produced strong revenue and profit growth in a highly leveraged environment. Under her vision and direction the company launched the highly successful SnackWell’s line which pioneered low-fat snacking.
Ms. Marram is a director of Ford Motor Company, The New York Times Company and Eli Lilly and Company as well as several private companies and non-profit institutions.
Ms. Marram received her B.A. from Wellesley College and her M.B.A. from Harvard Business School.
Short Biography -
David O. Zenker, Jr. Senior Managing Director
David O. Zenker, Jr. has been a member of Brock Capital Group LLC since 2003. He is an investment banker, principal and advisor specializing in the conception, planning and funding of start-up and early-stage companies whose product or service represents a paradigm shift that offers a self-evident, marked improvement over current standards. Mr. Zenker’s particular areas of interest are biotech, medical devices, alternative energy and sustainable business models with commercial and social significance.
David O. Zenker, Jr. has been a member of Brock Capital Group LLC since 2003. He is an investment banker, principal and advisor specializing in the conception, planning and funding of start-up and early-stage companies whose product or service represents a paradigm shift that offers a self-evident, marked improvement over current standards. Mr. Zenker’s particular areas of interest are biotech, medical devices, alternative energy and sustainable business models with commercial and social significance.
Mr. Zenker began his career in 1977 in the Investment Analysis and Research Department at J. Henry Schroder-Wagg in London. In 1978, he formed a partnership, Frith, Kirk & Zenker, providing management and marketing consulting services to European companies operating in the Arabian Gulf. He was based in Sharjah, U.A.E. where to complement his consulting work, he developed and managed under the direction of Frederick Pittera, an American pioneer in the exhibition industry, the Arabian Gulf’s leading exhibition, conference and entertainment center from 1978 – 1982. Following the overthrow of the Shah of Iran in 1979, the assassination of Egyptian President Sadat in 1981 and the general economic downturn of the region, in mid-1982 Mr. Zenker returned to the U.S. where for two summer seasons he was the Executive Director of the Waterloo Foundation for the Arts, overseeing the foundation’s historic village and music festival in Stanhope, NJ. In 1983, Mr. Zenker joined the fixed income department at Bear Stearns in New York, working first in high yield bonds and then specializing in bankruptcies and restructurings. He subsequently worked in the same field at Oppenheimer & Co. from June 1988 to June 1991 and Jefferies & Co. from July 1991 to April 1993. Following Jefferies, he served as President of Van Beuren Capital Management where he acted as both principal and advisor in connection with private equity investments related to energy, life sciences, real estate, gaming, advertising and general industrial manufacturing. Mr. Zenker has a B.A. from Brown University and a M.B.A. from the Wharton School of Business.
Short Biography -
Jean D. Hamilton Senior Managing Director
CEO, diversified financial services companies. Operating and investment expertise. Director of public and private companies in insurance, financial services, money management. Director and committee member of non-profit entities.
Currently, RenaissanceRe Holdings Director, First Eagle Funds and First Eagle Variable Funds Trustee, Chair of the Thomas Cole National Historic Site Investment Committee, and member of the Liz Claiborne and Art Ortenberg Foundaiton Investment Advisory Committee.
Former CEO of Prudential Institutional, EVP of Prudential Financial, President of Prudential Capital, President of Prudential Asset Sales and Syndications, and SVP of The First National Bank of Chicago (now J.P. Morgan Chase).
University of Illinois B.S.; University of Chicago M.B.A.
Jean D. Hamilton serves as a board director and is a member of Brock Capital Group LLC, a full service investment bank providing strategic advice and implementation support. Ms. Hamilton has extensive experience as a board director and in heading companies. She is involved with a variety of not-for-profit organizations.
Ms. Hamilton serves on the board of RenaissanceRe Holdings Ltd. where she has served as Chair and is a member of the Corporate Governance and Compensation Committee. Also, she serves on the Transaction and Offerings Committees, and has served as a member of the Investment Committee. She also serves on the boards of First Eagle Funds and First Eagle Variable Funds where she is Chair of the Board Valuation and Liquidity Committee and a member of the Audit and Insurance Committees. Ms. Hamilton is on the Investment Advisory Committee of the Liz Claiborne and Art Ortenberg Foundation and is Chair of the Investment Committee for the Thomas Cole National Historic Site.
At Prudential Financial, Ms. Hamilton served in a variety of management roles. Ms. Hamilton was an Executive Vice President of Prudential Financial, Inc. and Chief Executive Officer of Prudential Institutional, which under her leadership grew in revenues to more than $6 billion. Ms. Hamilton was responsible for evaluating and operating each of the insurance, banking, financial services and real estate businesses within the Prudential Institutional group. Following determination of the strategic fit of these businesses within Prudential and their profit potential, Ms. Hamilton successfully implemented a variety of plans to optimize the value of these businesses. These plans included internal growth, mergers, start-ups, restructurings, sales and discontinuation of various businesses.
Prior to being named Chief Executive Officer of Prudential Institutional, Ms. Hamilton was President of Prudential Capital Group, a private securities asset manager and originator responsible for a portfolio in excess of $20 billion in a wide range of industries and at multiple layers of the capital structure. Prior to holding this position, Ms. Hamilton was President of Prudential Asset Sales and Syndications, Inc., a seller and syndicator of private placement securities, and an entity in whose creation she was involved.
Before joining Prudential Financial, Ms. Hamilton was a Senior Vice President and Head of the Northeastern Corporate Banking Department for The First National Bank of Chicago, now J.P. Morgan Chase.
Ms. Hamilton has a BS degree in Communications from the University of Illinois and an MBA with concentrations in Finance and Accounting from the University of Chicago.
Short Biography -
Former CEO, diversified financial services; professional director; economist; Former Federal Reserve Bank president.
Director and/or lead director, Norfolk Southern Corporation, Eli Lilly, Simon Property Group, Fannie Mae, T. Rowe Price Funds, U.S. Russia Investment Fund.
Former Managing Director, Marsh & McLennan Companies; Managing Director, Bankers Trust; Chairman & CEO, Bank One of Cleveland; President, Federal Reserve Bank of Cleveland; Treasurer, Bell Telephone Company of Pennsylvania; Director, TRW, Rubbermaid, British Petroleum, Georgia-Pacific, The Rockefeller Foundation.
Pomona College B.A.; Johns Hopkins University Ph.D.
Karen N. Horn is a member of Brock Capital Group LLC.
Previously, she has served as a Managing Director at Marsh & McLennan Companies, where she was President of Global Private Client Services, providing Risk Management and Insurance services to high net-worth individuals and families worldwide. Ms. Horn was Managing Director at Bankers Trust, Chairman and CEO of Bank One, President of the Federal Reserve Bank of Cleveland, Treasurer of the Bell Telephone Company of Pennsylvania, Vice President and Economist at First Bank of Boston, and an Economist at the Board of Governors of the Federal Reserve.
Board and Committee memberships include the Norfolk Southern Corporation,Simon Property Group, T. Rowe Price Mutual Funds, The U. S. Russia Investment Fund, the National Bureau of Economic Research, Eli Lilly & Company, the Council on Foreign Relations, Georgia-Pacific Corporation, TRW, Inc., The Rockefeller Foundation, Rubbermaid Corporation, and Bipartisan Commission on Entitlements.
Ms. Horn has a B.A. from Pomona College and a Ph.D. in Economics from Johns Hopkins University.
Short Biography -
Investment banker, philanthropist, and private investor.
Manager, Carl H. Pforzheimer & Co.; Board member and chair of numerous charities and educational institutions including the New York Public Library, Lincoln Center, Pace University, Visiting Nurse Service of New York and Horace Mann School; Director of boards including U.S. Trust and Ampco-Pittsburg Corp.; Designated Representative of the State Comptroller for the Municipal Assistance Corporation for the City of New York. President, Harvard Alumni Association.
Harvard College A.B.; Harvard Business School M.B.A.
Carl H. Pforzheimer, III is a Senior Managing Director at Brock Capital Group LLC and the Manager of Carl H. Pforzheimer & Co., an investment banking firm established in 1901.
Mr. Pforzheimer is currently the Director of Ampco-Pittsburgh Corporation, the Carl and Lilly Pforzheimer Foundation, Inc., the Visiting Nurse Service of New York, the Lincoln Center Institute, and the Bulgarian American Enterprise Fund. He is the current Treasurer of UrbanGlass, formerly the New York Experimental Glass Workshop, Inc. Previously, Mr. Pforzheimer was a Director of the Delaware Management Holdings, Inc., Mark Controls Corporation, the Volunteer Urban Consulting Group, Friends of Scarsdale Library, and Harvard Business School Club of New York, Inc.
Mr. Pforzheimer is a member on the Board of Trustees for the Hoff-Barthelson Music School, the Corning Museum of Glass, the National Humanities Center, and the New York Public Library. He is the current Executive Committee Member and Chairman of the Board of Trustees at Pace University. Mr. Pforzheimer was previously the Chairman of the Board of Horace Mann-Barnard School, continuing on now as an honorary member. He served as Treasurer and Executive Committee member for the Caramoor Center for Music and the Arts, Inc., and was a Designated Representative of the State Comptroller for the Municipal Assistance Corporation for the City of New York. Mr. Pforzheimer was on the Board of Trustees of the Scarsdale Foundation and has served as President of the Scarsdale Union Free School District Board of Education.
Board memberships include the Harvard University Board of Overseers’ Visiting Committee on University Resources, the International Executive Service Corps Advisory Council and the Harvard University Faculty of Arts and Science Financial Aid Council. Additionally, Mr. Pforzheimer is on the Advisory Board of Program in Nonprofit and Leadership for the Harvard University John F. Kennedy School of Government. Prior board memberships include the Visiting Committee to the Center for Middle Eastern Studies, the Scarsdale Planning Board, the New York Public Library Committee on Research Libraries, and the Lincoln Center for the Performing Arts, Inc. Investment Committee.
Mr. Pforzheimer received his A.B. from Harvard College and his Masters in Business Administration from Harvard business School.
Short Biography -
Alan J. Biloski, Ph.D. Senior Managing Director
Former Head of Pharmaceutical/Biotech M&A at Merrill Lynch; Founder and Global Head of Healthcare Group at Wasserstein Perella; alumnus of M&A Group at First Boston. >$150 Billion in career transaction volume. Director, The Boyce Thompson Institute for Plant Research.
Yale University, B.S, M.S.; Cornell University, M.S., Ph.D.; Columbia University M.B.A
Alan Biloski works with high-quality pharmaceutical and biotech companies, and their major investors, to optimize business and financial strategies. His multi-disciplinary 30+ year career in the healthcare field – with experience as a scientist, a big pharma employee, a venture capitalist and an investment banker – enables him to rapidly bring forward practical and actionable ideas to help clients achieve the best possible valuation.
Dr. Biloski has led the seed round financings of a number of life science start-up companies in a diverse array of fields ranging from big data/AI (GNS Healthcare) to biotech (Advanced Medicine) and pharmaceutical services (Advion). As the lead pharma and biotech partner at Brock Capital, Dr. Biloski works with the independent fiduciary and family office groups to focus Brock Capital’s Opportunity Fund on the evaluation of direct investments in promising new companies.
Dr. Biloski’s prior experience includes 11 years of service as Senior Lecturer on the faculty of the Samuel Curtis Johnson Graduate School of Management at Cornell University where he led the Investment Banking Immersion and supported the practicums for the Research, Sales and Trading and Managerial Finance Immersions. While there, his students secured over 250 first tier investment banking jobs on Wall Street.
After a 15-year career in M&A banking, Dr. Biloski retired as Managing Director of Merrill Lynch in April 2001. He had joined the firm’s Healthcare Group in July 1998 and advised clients on approximately $100 billion of M&A transactions, including Pfizer’s unsolicited bid for Warner Lambert, MedImmune’s acquisition of US Bioscience, the sale of Mycogen to Dow Chemical and Alkermes acquisition of Advanced Inhalation Research. In November 2000, he advised Immunex on a comprehensive restructuring that included major governance changes, the dilution of AHP’s ownership interest in Immunex from 55% to 41% and the largest biotech equity offering in history with the sale of $3.2 billion in Immunex common stock. He also led efforts that produced two of the largest private placements in biotech history, raising $160 million for Advanced Medicine (now Theravance) in 1999 and $110 million for Eyetech in 2000.
As founder of the Healthcare Group at Wasserstein Perella & Co. in 1991, Dr. Biloski assembled a group of 12 professionals who concluded over $40 billion in pharmaceutical, health service, and medical device deals. Through his specialization in pharmaceuticals, Dr. Biloski has been responsible for a number of landmark transactions such as SmithKline Beecham’s acquisition of Sterling Winthrop (largest OTC deal), the sale of Sterling Winthrop North American to Bayer (second largest OTC deal), the sale of SmithKline Beecham’s animal health business to Pfizer (largest animal health deal), SmithKline Beecham’s purchase of DPS from United Healthcare (third largest pharmacy benefits manager deal), and the Chapter 11 reorganization of A.H. Robins (largest pharmaceutical product liability and bankruptcy).
Dr. Biloski is also an alumnus of the Healthcare Mergers and Acquisitions Group at the First Boston Corporation. While there he assisted senior bankers in over $10 billion in healthcare M&A transactions including the sale of A. H. Robins to American Home Products, the sale of Lyphomed to Fujisawa Pharmaceuticals, Bayer AG’s purchase of Cooper Technicon and SmithKline Beecham’s acquisition of International Clinical Laboratories.
He has experience as a venture capitalist, through the Princeton, NJ firm of Johnston Associates, and as a strategic planner with Merck Sharp and Dohme Research Laboratories. Dr. Biloski also served on the Board of Directors of Merrill Lynch Ventures where he had primary responsibility for evaluating new investments in the health care field. Dr. Biloski has assisted early stage life science companies in financing their businesses, raising $15 million for Advion through Skyline and Perseus-Soros and $5.5 million for Gene Network Sciences (now ViaScience). In addition, he assists management in strategic transactions such as advising Adolor in structuring an alliance with Glaxo for the codevelopment and co-marketing of Alvimopan, advising Eyetech in structuring an alliance with Pfizer for the co-development and co-marketing of Macugen, advising Sagres Discovery in a merger with Chiron and Spectral Genomics in an asset sale to Perkin Elmer.
In 2004 Dr. Biloski was elected to the Board of Directors of the Boyce Thompson Institute (www.bti.cornell.edu), one of the world’s leading independent institutions for plant research. From 2005-2011 Dr. Biloski served as Vice Chairman of the Board of Directors and chaired the BTI Investment Committee which is charged with managing the Institutes ~$100 MM endowment and since that time he has transitioned to head the Finance Committee. He holds a Ph.D. in synthetic organic chemistry from Cornell University and a M.B.A. with distinction from Columbia University. He was elected to Phi Beta Kappa at Yale University and graduated summa cum laude with a B.S./M.S. in Chemistry.
Short Biography - About Brock
- Investment Banking
- Advisory Services
- Fiduciary Services
- Select Clients
- Our Team
- Careers
- Engagements
- Contact
- Member Login
© 2014-2022 Brock Capital Group LLC. All rights reserved.